To evaluate the role of SLC25A1 as a ferroptosis inhibitor, we silenced its expression in A375 and A549 lung cancer cells and observed increased sensitivity to ferroptosis triggered by RSL3, erastin, and cystine deprivation (Fig. 1C–E; Appendix Fig. S1A–D). Here, SLC25A1 is linked to lung carcinoma.